Carl Zeiss Meditec AG (0DHC)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 34.64 |
|---|---|
| 52-week range | 22.20 – 46.47 |
| Return, 1 month / 3 months | +17.0% / +27.6% |
| Return, 1 year / 3 years | −26.0% / −52.0% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 45.4% |
| Worst drawdown (1 year) | -50.5% |
| Average daily value traded | 0.71M EUR |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Carl Zeiss Meditec makes medical devices used in eye care and microsurgery. Its products include surgical microscopes, diagnostic instruments for examining the eye, and implants such as intraocular lenses used in cataract surgery. The company supplies hospitals, eye clinics and surgeons who treat conditions of the eye and perform delicate procedures. It is based in Jena, Germany, and operates as part of the wider Zeiss group of optical and medical technology businesses.
Carl Zeiss Meditec AG trades under the code 0DHC on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Carl Zeiss Meditec AG (0DHC) trades on the London Exchange in UK. It last closed at EUR 34.64 on 21 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 1,962 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 26.0% and over the last three months it rose 27.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 69 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 21.7% | ||
| From 52-week high | -25.0% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 27.6% | ||
| 6-month return | 28.7% | ||
| 12-month return, skipping the last month | -36.8% | ||
| Stability (higher is calmer) | 26 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 45.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.5% | ||
| Liquidity | 49 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.71M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.9% |
|---|---|
| 1 month | +17.0% |
| 3 months | +27.6% |
| 6 months | +28.7% |
| 1 year | −26.0% |
| 3 years | −52.0% |
| 5 years | −78.6% |
Signals
| 50-day / 200-day average | 31.56 / 28.47 |
|---|---|
| Golden / death cross (60 days) | Golden, 33 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.97 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Mar 2026 | EUR 0.5500 |
| 27 Mar 2025 | EUR 0.6000 |
| 22 Mar 2024 | EUR 1.1000 |
| 23 Mar 2023 | EUR 1.1000 |
| 31 Mar 2022 | EUR 0.9000 |
| 28 May 2021 | EUR 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.